➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
Merck
Moodys
McKinsey
McKesson

Last Updated: September 20, 2021

DrugPatentWatch Database Preview

Claims for Patent: 5,688,688

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 5,688,688
Title: Vector for expression of a polypeptide in a mammalian cell
Abstract:Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to prepare antibodies, where both the polypeptides and antibodies may be employed as diagnostic reagents or in therapy, e.g., vaccines and passive immunization. The sequences provide detection of the viral infectious agents associated with the indicated syndromes and can be used for expression of antigenic polypeptides.
Inventor(s): Luciw; Paul A. (Davis, CA), Dina; Dino (San Francisco, CA), Rosenberg; Steven (Oakland, CA), Chapman; Barbara S. (Berkeley, CA), Thayer; Richard M. (Alamo, CA), Haigwood; Nancy L. (Bellevue, WA)
Assignee: Chiron Corporation (Emeryville, CA)
Application Number:08/288,336
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 5,688,688
Patent Claims:1. A vector for expression of a polypeptide in a mammalian cell comprising a first polynucleotide sequence that comprises:

a) an upstream SV40 origin of replication;

b) a downstream SV40 polyadenylation region; and

c) a transcription regulatory region from human cytomegalovirus immediate early region HCMV IE1, wherein the transcription regulatory region includes the first HCMV IE1 intron proximal to the 3' end of the HCMV IE1 promoter, is interposed between the SV40 origin of replication and the SV40 polyadenylation region, and is capable of directing the transcription of a polypeptide coding sequence operably linked downstream from the transcription regulatory region.

2. The vector of claim 1, wherein the polynucleotide sequence further comprises a linker that comprises a restriction site for insertion of the coding region of a polypeptide.

3. The vector of claim 2, wherein the restriction site is a SalI site.

4. The vector of claim 1, wherein the SV40 polyadenylation region comprises the SV40 polyadenylation sequence present in plasmid pSV7d.

5. The vector of claim 1, wherein the SV40 origin of replication comprises the SV40 origin of replication sequence present in plasmid pSVT2.

6. The vector of claim 1, further comprising a selectable marker.

7. The vector of claim 5, wherein the selectable marker is a polynucleotide sequence that encodes ampicillin resistance.

8. The vector of claim 1, further comprising a bacterial origin of replication.

9. The vector of claim 1, wherein the polynucleotide sequence comprises the HCMV sequences present in plasmid pCMV6ARV120tpa, ATCC Accession No. 68249.

10. The vector of claim 2, further comprising a coding region that encodes a polypeptide, inserted at the restriction site.

11. The vector of claim 10, further comprising a region encoding a signal sequence effective in directing the secretion of the polypeptide encoded by the coding region, positioned upstream from the coding region.

12. The vector of claim 11, wherein the signal sequence is derived from the human tissue plasminogen activator leader sequence.

13. A vector produced by the process comprising linking together in an operative manner:

a) a SV40 origin of replication;

b) a SV40 polyadenylation region; and

c) a transcription regulatory region from human cytomegalovirus immediate early region HCMV IE1, wherein said regulatory region includes the first HCMV IE1 intron proximal to the 3' end of the HCMV IE1 promoter and is capable of directing the transcription of a polypeptide coding sequence operably linked downstream therefrom.

14. The vector of claim 13, wherein the vector is arranged in the same manner as plasmid pCMV6a.

15. A method for producing a vector for expression of a polypeptide in a mammalian cell comprising:

a) providing a first polynucleotide molecule that comprises a SV40 origin of replication;

b) providing a second polynucleotide molecule that comprises a SV40 polyadenylation region;

c) providing a third polynucleotide molecule that comprises a transcription regulatory region from human cytomegalovirus immediate early region HCMV IE1, wherein said regulatory region includes the first HCMV IE1 intron proximal to the 3' end of the HCMV IE1 promoter; and

d) linking the SV40 origin of replication, the SV40 polyadenylation region and the regulatory region from HCMV IE1 together to form a vector that is capable of effecting the transcription of a polypeptide coding sequence operatively linked downstream from the regulatory region.

16. A method for producing the vector of claim 1, comprising introducing the vector into a host cell and allowing the host cell to generate a plurality of said vectors.

17. An isolated nucleic acid molecule comprising an enhanced promoter, wherein the enhanced promoter comprises the human cytomegalovirus immediate early region HCMV IE1 promoter and the first intron proximate to the 3' end of the HCMV IE1 promoter.

18. The nucleic acid molecule of claim 17, wherein the promoter region is derived from a subclone of human cytomegalovirus (Towne strain).

19. A vector for expression of a polypeptide in a mammalian cell, comprising the nucleic acid molecule of claims 17, wherein the nucleic acid molecule is capable of directing the transcription of a polypeptide coding sequence operably linked downstream of the nucleic acid molecule.

20. The vector of claim 19, further comprising an origin of replication operably linked upstream of the nucleic acid molecule.

21. The vector of claim 19, further comprising a polyadenylation region operably linked downstream of the nucleic acid molecule.

22. A vector for expression of a polypeptide in a mammalian cell, comprising:

a) an upstream origin of replication;

b) a downstream polyadenylation region; and

c) the nucleic acid molecule of claim 17 interposed between the origin of replication and the polyadenylation region, wherein the enhanced promoter region is capable of directing the transcription of a polypeptide coding sequence operably linked downstream from the promoter region.

23. A method for constructing the vector of claim 19, comprising operatively linking together the nucleic acid molecule and the polypeptide coding sequence.

24. A method for producing the vector constructed in claim 23, comprising introducing the vector into a host cell that is capable of replicating the vector and allowing the host cell to replicate the vector.

Details for Patent 5,688,688

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04 ⤷  Free Forever Trial Chiron Corporation (Emeryville, CA) 2014-11-18 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04 ⤷  Free Forever Trial Chiron Corporation (Emeryville, CA) 2014-11-18 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04 ⤷  Free Forever Trial Chiron Corporation (Emeryville, CA) 2014-11-18 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
Johnson and Johnson
Medtronic
Harvard Business School
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.